Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

319P - A propensity score weighted study comparing two versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer

Date

16 Sep 2021

Session

ePoster Display

Topics

Cytotoxic Therapy

Tumour Site

Breast Cancer

Presenters

Herve Bischoff

Citation

Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689

Authors

H. Bischoff1, C. Bigot1, F. Moinard1, C. Pflumio1, C. Fischbach1, M. Kalish Weindling1, M. Alt1, L. Pierard1, T. Petit1, M.F. Demarchi1, J.E. Kurtz1, D. Karouby2, P. Coliat2, D. Cox3, X. Pivot1, L. Bender1, P. Trensz1

Author affiliations

  • 1 Medical Oncology Department, Institut de Cancérologie Strasbourg Europe, 67033 - Strasbourg/FR
  • 2 Pharmacy, Institut de Cancérologie Strasbourg Europe, 67033 - Strasbourg/FR
  • 3 Statistics, Institut de Cancérologie Strasbourg Europe, 67033 - Strasbourg/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 319P

Background

A 4-weekly schedule of Pegylated Liposomal Doxorubicin (PLD) has been approved for the treatment of Metastatic Breast Cancer (MBC). Phase II trials have suggested interest for a 2-weekly regimen. The aim of this study was to compare efficacy and safety of these two modalities.

Methods

Data from MBC patients treated with PLD at two hospitals in Strasbourg between 2011 and 2021 were retrospectively collected. The objective was to demonstrate the non-inferiority of the 2-weekly versus the 4-weekly schedule in terms of 6-month progression free survival (PFS) rates. The non-inferiority margin was defined based on a pooled analysis of previous anthracycline trials in MBC. A propensity score to receive the 4-weekly versus the 2-weekly schedule was estimated using a multivariate logistic regression. Survival analyses using Cox regression models weighted by the propensity score were performed to compare 2-weekly versus 4-weekly regimens.

Results

A total of 192 patients treated with PLD for MBC were included. Among them, 96 (50%) underwent the 2-weekly PLD schedule. In the modified intent-to-treat (mITT) population (n=191), the median age was 63 years. The median number of previous systemic therapies was 4. Anthracyclines were previously used in in 63.9% of cases for Early Breast Cancer (EBC) and in 7.8% for MBC. There was a comparable distribution of adverse events in both groups in the ITT population. Treatment was discontinued because of adverse events in 15.7% of overall patients, well balanced between the two groups. The most common all-grade toxicity was cutaneous, concerning 30.4% of patients. There was no death presumably related to PLD administration. The median follow-up was 10.1 months. The progression-free survival analyses weighted by propensity score will be presented.

Conclusions

This study was the first to compare 2-weekly versus 4-weekly administration of PLD with the aim to demonstrate non-inferiority between the two modalities.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Philippe Trensz.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.